Agostini Aubert, Miquel Laura, Herman-Demars Hélène, Frantz Sandrine, Sicot Marie
Department of Obstetrics and Gynecology, Assistance Publique - Hôpitaux de Marseille, la Conception Hospital, Aix Marseille Université, 147 Boulevard Baille, 13005, Marseille, France.
Medical Department, Nordic Pharma SAS, Paris, France.
Pain Ther. 2023 Apr;12(2):563-574. doi: 10.1007/s40122-023-00477-2. Epub 2023 Feb 25.
Women frequently report pain associated with medical termination of pregnancy (MToP), and its management can differ largely between centres. This study aimed at evaluating in real-life settings pain related to MToP and its management in France.
This was a non-interventional prospective, longitudinal study run in 23 centres between 2015 and 2016 that included 893 pregnant women. Pain was reported by women prior any curative analgesic intake (CAI) through a five-level Likert scale (absence, mild, moderated, severe, extreme). Modalities of analgesic prophylaxis prescription (APP) and intake (API) and CAI were collected. Risk factors were investigated using ordinal logistic regression (for pain) or logistic regression (for CAI) with stepwise selection of variables.
APP was prescribed to 657 (73.7%) women irrespective of the gestational age, among whom 386 (73.7%) took the treatment. Out of 740 women who documented their pain symptoms prior to any CAI, few declared no pain (n = 94, 12.7%) or intense pain (n = 88, 11.9%). The majority reported mild or moderate pain (n = 558, 75.4%). On multivariate analysis adjusted on gestational age, increasing initial [odds ratio (OR) 1.25, 95% confidence interval (CI) 1.06-1.47] or total dose (OR 1.15, 95% CI 1.05-1.26) of misoprostol taken were independent factors associated with risk of more pain. When adjusting for gestational age, initial dose of misoprostol (OR 1.69, 95% CI 1.45-2.66) and pain experienced (OR 3.58, 95% CI 2.82-4.55) were significantly associated with higher risk of CAI while API (OR 0.52, 95% CI 0.36; 0.75) was negatively associated.
Most of the women received an APP, but not all used it. API and gestational age were not related to different risks of more pain following MToP, whereas history of at least one child showed a negative association. Higher doses of misoprostol were strongly associated with both pain and CAI. API was associated with a decreased risk of CAI.
女性经常报告与药物流产相关的疼痛,而且不同医疗中心对其处理方式差异很大。本研究旨在评估法国实际临床环境中与药物流产相关的疼痛及其处理情况。
这是一项非干预性前瞻性纵向研究,于2015年至2016年在23个医疗中心开展,纳入了893名孕妇。女性在服用任何治疗性镇痛药(CAI)之前,通过五级李克特量表(无、轻度、中度、重度、极重度)报告疼痛情况。收集了预防性镇痛药物处方(APP)、用药(API)及CAI的相关信息。采用有序逻辑回归(针对疼痛)或逻辑回归(针对CAI)逐步选择变量来研究危险因素。
无论孕周如何,657名(73.7%)女性接受了APP,其中386名(73.7%)服用了该药物。在740名在服用任何CAI之前记录了疼痛症状的女性中,很少有人宣称无疼痛(n = 94,12.7%)或剧痛(n = 88,11.9%)。大多数人报告为轻度或中度疼痛(n = 558,75.4%)。在根据孕周进行调整的多因素分析中,米索前列醇初始剂量增加(比值比[OR] 1.25,95%置信区间[CI] 1.06 - 1.47)或总剂量增加(OR 1.15,95% CI 1.05 - (此处原文有误,应为1.26))是与疼痛加剧风险相关的独立因素。在根据孕周进行调整时,米索前列醇初始剂量(OR 1.69,95% CI 1.45 - 2.66)和所经历的疼痛(OR 3.58,95% CI 2.82 - 4.55)与CAI风险显著相关,而API(OR 0.52,95% CI 0.36;0.75)与之呈负相关。
大多数女性接受了APP,但并非所有人都使用了。API和孕周与药物流产后疼痛加剧的不同风险无关,而至少有一个孩子的生育史呈负相关。较高剂量的米索前列醇与疼痛和CAI均密切相关。API与CAI风险降低相关。